ETV1 Translocations in Prostate Cancer
Author Information
Author(s): Attard G, Clark J, Ambroisine L, Mills I G, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie C E, Fletcher A, De Bono J S, Scardino P, Cuzick J, Cooper C S
Primary Institution: Institute of Cancer Research
Hypothesis
What is the clinical significance of ETV1 gene alterations in prostate cancer?
Conclusion
ETV1 gene rearrangements are correlated with higher Gleason scores and PSA levels but are not linked to poorer survival outcomes.
Supporting Evidence
- ETV1 gene alterations were found in 5.4% of prostate cancer cases.
- ETV1 rearrangements were correlated with higher Gleason scores.
- ETV1 alterations were associated with higher PSA levels at diagnosis.
- ETV1 rearrangements were not linked to poorer survival outcomes.
Takeaway
This study looked at prostate cancer samples to see if changes in a gene called ETV1 were important. They found that while these changes are common, they don't seem to make people live shorter lives.
Methodology
A fluorescence in situ hybridisation (FISH) assay was used to screen for ETV1 gene rearrangements in prostate cancer samples.
Limitations
The study was limited by the small amounts of RNA that could be extracted from formalin-fixed tissues.
Participant Demographics
The median age of diagnosis was 70 years, with most men diagnosed after the age of 65.
Statistical Information
P-Value
P=0.001
Confidence Interval
CI=0.87–2.53
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website